Study of golidocitinib plus pomalidomide for relapsed/refractory PTCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, golidocitinib and pomalidomide, for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of PTCL that has come back or not responded to at least one prior treatment.
- You are between 18 and 80 years old.
- You have at least one tumor that can be measured on scans (lymph node at least 1.5 cm or other site at least 1 cm).
- You are in fairly good general health (able to do daily activities with some help if needed).
- Your blood counts and organ function (kidney, liver, heart) are within acceptable ranges.
- You have not had certain treatments (like chemo, radiation, or stem cell transplant) in the past 3-6 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This study tests an oral pill called golidocitinib (a JAK1 inhibitor) as the first treatment for people newly diagnosed with peripheral T-cell lymphoma. The pill targets a pathway that cancer cells use to grow, and the goal is to shrink tumors or slow the disease.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This study looks at how well a medicine called golidocitinib, given alone or with other treatments, works for people with peripheral T-cell lymphoma (a type of blood cancer). It is a real-world study, meaning it follows patients who are already receiving this treatment in regular medical care.
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
Hear when a new Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.